Together with other studies (Martínez et al., 2009; Dixon et al., 2014; Babić Leko et al., 2020), our work supports the inclusion of COMT into polygenetic risk scores for MCI and AD as it interacts with ApoE status for selective cognitive domains associated with these conditions. This evidence concerns the gene APOE and Alzheimer disease.